- Home
- BBIO vs PEN Comparison
BBIO vs PEN Comparison
Compare BBIO & PEN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | BBIO | PEN |
|---|---|---|
| Founded | 2015 | 2004 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Medical/Dental Instruments |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 15.3B | 13.2B |
| IPO Year | 2019 | 2015 |
Fundamental Metrics
Financial Performance| Metric | BBIO | PEN |
|---|---|---|
| Price | $70.20 | $338.48 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 24 | 17 |
| Target Price | $83.00 | ★ $357.33 |
| AVG Volume (30 Days) | ★ 2.4M | 539.2K |
| Earning Date | 05-22-2026 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 1155.56 |
| EPS | N/A | ★ 4.52 |
| Revenue | $502,076,000.00 | ★ $1,403,665,000.00 |
| Revenue This Year | $88.86 | $14.20 |
| Revenue Next Year | $74.11 | $13.60 |
| P/E Ratio | ★ N/A | $74.80 |
| Revenue Growth | ★ 126.26 | 17.50 |
| 52 Week Low | $28.33 | $221.26 |
| 52 Week High | $84.94 | $362.41 |
Technical Indicators
Market Signals| Indicator | BBIO | PEN |
|---|---|---|
| Relative Strength Index (RSI) | 50.29 | 49.57 |
| Support Level | $61.95 | $338.08 |
| Resistance Level | $78.20 | $344.07 |
| Average True Range (ATR) | 2.75 | 2.26 |
| MACD | 0.64 | -0.40 |
| Stochastic Oscillator | 56.57 | 44.82 |
Price Performance
Historical ComparisonAbout BBIO BridgeBio Pharma Inc.
BridgeBio Pharma is a biotechnology company focused on discovering, developing, testing, and delivering transformative treatments for patients with genetic diseases. The company has four programs in its late-stage pipeline focusing on Mendelian disorders, oncology, and gene therapy. One of its key programs, Attruby (acoramidis), is an orally administered small molecule designed to stabilize tetrameric transthyretin for the treatment of transthyretin amyloid cardiomyopathy.
About PEN Penumbra Inc.
Domiciled in the US, Penumbra designs, manufactures, and markets an array of thrombectomy and embolization devices and equipment to mechanically remove blood clots. The firm sells mainly to hospitals and physicians. These minimally invasive devices are primarily used in the acute care setting for patients with stroke, pulmonary embolism, deep vein thrombosis, cranial aneurysms, and other vascular diseases.